Kate Moodie

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 172 citations

Urology, Overall Survival, Genitourinary Cancer +8

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

Sheau Wen Lok, James R. Whittle, François Vaillant et al. · Cancer Discovery · 2019 · 143 citations · Full text

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

Despina Handolias, Anne Hamilton, Renato Salemi et al. · British Journal of Cancer · 2010 · 128 citations · Full text

FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy

Fiona Day, Emma Link, Samuel Y. Ngan et al. · British Journal of Cancer · 2011 · 65 citations · Full text